Stage III Prostate Cancer AJCC v8 Clinical Trial
Official title:
A Pilot Study of 7 Tesla MRI Neuroimaging Biomarkers of Prostate Cancer-Related Cognitive Impairment
This trial studies 7 Tesla magnetic resonance imaging (MRI) in diagnosing cognitive impairment in patients with prostate cancer that has not spread to other places in the body (non-metastatic) and who have or have not received androgen deprivation therapy (ADT). The MRI machine uses a strong magnet and radio wave to make images of the inside of the body. A stronger magnetic field allows greater signals and more detailed visualization of the structure and function of human body. Giving 7 Tesla MRI may help doctors learn if patients that receive ADT show more signs of cognitive dysfunction or brain fog compared to patients to patients that do not receive ADT.
PRIMARY OBJECTIVES: I. Observe longitudinal changes in structural connectivity using T1-weighted and diffusion tensor MRI in men with non-metastatic prostate cancer on current ADT versus those who were not. II. Observe longitudinal changes in brain functional connectivity using resting-state functional (rsf) MRI. III. Observe longitudinal changes in brain metabolic profiles evaluated by MR spectroscopy (MRS). IV. Exploratory assessment of correlation between testosterone and prostate specific antigen (PSA) levels with MRI measures and cognitive measures. SECONDARY OBJECTIVES: I. To assess the feasibility and acceptability of this approach using sequential 7T MRI in prostate cancer patients either receiving ADT or not. OUTLINE: Patients undergo 7 Tesla MRI over 30-90 minutes at baseline and at 6-9 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03218826 -
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Recruiting |
NCT04981834 -
Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer
|
N/A | |
| Completed |
NCT04976257 -
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
|
Early Phase 1 | |
| Recruiting |
NCT06173362 -
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
|
Phase 2 | |
| Suspended |
NCT03899987 -
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
|
Phase 2 | |
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
| Not yet recruiting |
NCT06129851 -
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05487846 -
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
|
N/A | |
| Recruiting |
NCT05946213 -
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03570827 -
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
|
Phase 2 | |
| Recruiting |
NCT03987386 -
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT06325046 -
Evaluating Changes in Quality of Life After Near Margin-less Adaptive Radiation Therapy Compared to Standard Stereotactic Ablative Body Radiotherapy in Localized Prostate Cancer
|
N/A | |
| Recruiting |
NCT04134260 -
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
|
Phase 3 | |
| Completed |
NCT03177460 -
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05320406 -
RElugolix VErsus LeUprolide Cardiac Trial
|
Phase 4 | |
| Completed |
NCT04067960 -
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
|
Early Phase 1 | |
| Suspended |
NCT04037254 -
Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT05869682 -
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
|
Phase 2 | |
| Recruiting |
NCT06389786 -
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
|
N/A | |
| Recruiting |
NCT05877144 -
Low-Intensity Shockwave Therapy to Treat Erectile Dysfunction and Preserve Erectile Function After Prostate Cancer Surgery
|
N/A |